New hope for early lung cancer: immunotherapy after surgery may prevent return
NCT ID NCT07388524
First seen Feb 05, 2026 · Last updated Apr 28, 2026 · Updated 15 times
Summary
This study tests whether the immunotherapy drug atezolizumab can prevent stage I non-small cell lung cancer from returning after it has been completely removed by surgery. About 336 people who have had surgery for early-stage lung cancer will either receive atezolizumab or be watched closely without extra treatment. The goal is to see if the drug helps keep cancer away longer than just monitoring alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.